Agnosia for Pain
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Inhibiting the induced brain CYP2D reversed the change in oxycodone levels (1.2-fold; P > 0.1) and analgesia (1.1-fold; P > 0.3).
|
29266563 |
2019 |
Agnosia for Pain
|
0.020 |
Biomarker
|
disease |
BEFREE |
Inducing brain CYP2D with nicotine did not alter acute morphine analgesia (1.03-fold; p>0.8), or the rate of morphine tolerance (8.1%/day versus 7.6%; p>0.9).
|
28837793 |
2017 |
Agranulocytosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6.
|
11147929 |
2000 |
Alzheimer's Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease.
|
20859244 |
2011 |
Amelogenesis Imperfecta, Type IB
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope.
|
15000871 |
2004 |
Attention deficit hyperactivity disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Atomoxetine is a treatment for attention-deficit/hyperactivity disorder and is primarily eliminated via cytochrome P4502D6 (CYP2D6).
|
12621383 |
2003 |
Autoimmune Chronic Hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.
|
2466049 |
1989 |
Autoimmune Chronic Hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
Autoimmune hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |
Autoimmune hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.
|
2466049 |
1989 |
Autoimmune hepatitis type 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
Liver Kidney Microsomal autoantibody type 1(LKM1) directed to cytochrome P4502D6 (CYP2D6) characterises autoimmune hepatitis type-2 (AIH-2), but is also found in a proportion of chronic hepatitis C virus (HCV) infected patients, CYP2D6252-271 being a major B- cell autoepitope.
|
15000871 |
2004 |
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The gene encoding the phase I enzyme cytochrome P4502D6 (CYP2D6) has been previously investigated for its potential predictive role in the efficacy of breast cancer treatments such as tamoxifen, but its role in breast cancer susceptibility is unclear.
|
21527579 |
2011 |
Caffeine related disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
The five probe substrates were caffeine (2 mg/kg), bupropion (30 mg/kg), omeprazole (4 mg/kg), dextromethorphan (40 mg/kg), and midazolam (2 mg/kg) for CYP1A, CYP2B, CYP2C, CYP2D, and CYP3A, respectively.
|
29550976 |
2018 |
Carcinoma of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Taking this new information into account, we have reconsidered the potential influence of CYP2D6 polymorphism in lung cancer susceptibility by performing a comparative analysis of the overall mutational spectrum of CYP2D6 and of the rearrangements of CYP2D in 249 patients with lung cancer and in 265 control individuals matched on age, sex, hospital and residence area.
|
9511176 |
1998 |
Carcinoma of lung
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Cytochrome P4502D6, responsible for metabolizing many clinically important medications, also is linked to lung cancer risk.
|
7737047 |
1994 |
Catalepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Selective inhibition and induction of brain, but not liver, CYP2D decreased and increased catalepsy after acute haloperidol, respectively.
|
28454738 |
2017 |
Child Development Disorders, Pervasive
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Meta-analysis of GWAS of over 16,000 individuals with autism spectrum disorder highlights a novel locus at 10q24.32 and a significant overlap with schizophrenia.
|
28540026 |
2017 |
CYP2D6 polymorphism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Taking this new information into account, we have reconsidered the potential influence of CYP2D6 polymorphism in lung cancer susceptibility by performing a comparative analysis of the overall mutational spectrum of CYP2D6 and of the rearrangements of CYP2D in 249 patients with lung cancer and in 265 control individuals matched on age, sex, hospital and residence area.
|
9511176 |
1998 |
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat.
|
30195732 |
2018 |
Diabetes
|
0.010 |
Biomarker
|
disease |
BEFREE |
The simulated diabetes in CYP2D poor metabolizers showed reduced metabolic ratios for M1 enantiomers.
|
30502451 |
2019 |
Diabetes Mellitus
|
0.010 |
Biomarker
|
group |
BEFREE |
The simulated diabetes in CYP2D poor metabolizers showed reduced metabolic ratios for M1 enantiomers.
|
30502451 |
2019 |
Gilbert Disease (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Gilbert's syndrome, a genetic deficiency in bilirubin UDP-glucuronosyltransferase (UGT1A1), may dispose to increased toxicity of propafenone in poor metabolizers (PMs) of cytochrome P4502D6 because glucuronidation of propafenone is the major metabolic pathway for drug elimination in PMs.
|
10850406 |
2000 |
Head and Neck Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
However, the combinations of CYP1A1 (AA) and CYP2D6 (CC) genotypes decreased risk of HNC (OR 0.20; P = 0.006).
|
24449363 |
2014 |
Hepatitis C
|
0.020 |
Biomarker
|
disease |
BEFREE |
Anti-liver-kidney microsome antibodies (anti-LKM) occur in autoimmune hepatitis (AIH) type II and in a subset of patients with hepatitis C. Anti-LKM1 in AIH are directed against cytochrome P4502D6 (CYP2D6), but conflicting data exist concerning the specificity of anti-LKM in hepatitis C. The aim of this study was to evaluate binding specificities of anti-LKM antibodies in both diseases using novel test antigens as well as their inhibitory capacity on CYP2D6 enzyme activity.
|
10540193 |
1999 |